Pliant Therapeutics (PLRX) Stock: Buy, Sell, or Hold?
PLRX - Pliant Therapeutics, Inc. Common Stock
$1.04
-0.02 (-1.43%)
▼
5d:
-4.17%
30d:
-10.78%
90d:
-10.0%
WAIT
LOW Confidence
Analysis Updated: Oct 2, 2026 12:00 AM ET
Earnings: Nov 05, 2026
Get Alerted When PLRX Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
📊 MIXED SIGNALS: PLRX shows conflicting indicators. Wait for confirmation before entering.
📊 MIXED SIGNALS: PLRX shows conflicting indicators. Wait for confirmation before entering.
In-depth Analysis How we analyze
Valuation Analysis: PLRX is currently trading at $1.03, which is considered oversold relative to its 30-day fair value range of $1.08 to $1.16.
Technical Outlook: Technically, PLRX is in a downtrend. The price is currently testing key support at $1.03. A bounce from this level would confirm strength, while a break below could signal further downside.
Market Sentiment: PLRX scores 36/100 on our bottoming-setup gauge. Note this measures entry quality, not trend direction — a low score can mean the chart is extended after a strong run (don't chase) or still falling without stabilization; better entries typically come after a pullback toward the 20-day average. Wall Street analysts see significant upside, with an average price target of $2.00 (+93.2%). Current signals suggest waiting for a better entry point before initiating new positions.
Technical Outlook: Technically, PLRX is in a downtrend. The price is currently testing key support at $1.03. A bounce from this level would confirm strength, while a break below could signal further downside.
Market Sentiment: PLRX scores 36/100 on our bottoming-setup gauge. Note this measures entry quality, not trend direction — a low score can mean the chart is extended after a strong run (don't chase) or still falling without stabilization; better entries typically come after a pullback toward the 20-day average. Wall Street analysts see significant upside, with an average price target of $2.00 (+93.2%). Current signals suggest waiting for a better entry point before initiating new positions.
Quick Decision Summary
Current Position
OVERSOLD
Historical Trading Range
$1.08 -
$1.16
Company Quality Score
45/100
(HOLD)
Volume Confirmation
HIGH
Confidence Score
57.9%
All Signals
- BULLISH: Price oversold vs 30-day range
- BEARISH: Weak technical setup (36/100)
- BULLISH: High volume confirmation
- BULLISH: Trading 93.2% below Wall St target ($2.00)
- WARNING: Composite score 45/100 in the bottom quintile — this cohort historically lags the market
Trading Range Analysis
30-Day Trading Range
$1.08 -
$1.16
Current vs Trading Range
OVERSOLD
Support & Resistance Levels
Support Level
$1.03
Resistance Level
$1.15
Current Trend
Downtrend
Technical data as of
Oct 2, 2026
Fundamental Context
Forward P/E (Next Year Est.)
-0.81
Wall Street Target
$2.00
(+93.2%)
Revenue Growth (YoY)
-100.0%
Share & Embed Analysis
Last updated: October 02, 2026 5:26 PM ET
Data refreshes hourly during market hours. Next update: 6:26 PM
Data refreshes hourly during market hours. Next update: 6:26 PM
🔥 Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is PLRX showing a specific setup today?
Insider Activity (6 Months)
0
Buys
0
Sells
0
Net
NEUTRAL
Top Rated Biotechnology Stocks
Top-rated stocks in Biotechnology by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
NTLA
Intellia Therapeutics Inc |
STRONG BUY
29 analysts |
$24 | 54 HOLD |
|
REGN
Regeneron Pharmaceutical… |
STRONG BUY
25 analysts |
$851 | 48 HOLD |
|
JAZZ
Jazz Pharmaceuticals PLC |
STRONG BUY
18 analysts |
$293 | 67 BUY |
|
MLTX
MoonLake Immunotherapeut… |
STRONG BUY
16 analysts |
$29 | 51 HOLD |
|
ACAD
ACADIA Pharmaceuticals I… |
BUY
20 analysts |
$32 | 62 BUY |
